<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662166</url>
  </required_header>
  <id_info>
    <org_study_id>6/1801/2014</org_study_id>
    <nct_id>NCT02662166</nct_id>
  </id_info>
  <brief_title>MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer</brief_title>
  <acronym>MIB</acronym>
  <official_title>Magnetic Resonance Imaging of Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer (BC) as the most common malignancy arising from the urinary tract continues to
      be a major health problem. This prospective non-randomized study will enroll 150 patients
      undergoing magnetic resonance imaging (MRI) at different stages of their diagnostic and
      therapeutical process. The enrolled patients with suspected BC (BC) based on cystoscopy will
      have their initial MRI examination before transurethral resection of bladder tumor (TUR-BT)
      and biomarker collection. After pathology review of the histological specimens, patients will
      be treated according to standard clinical practice. The second MRI examination will be
      performed before therapeutic intervention, if TUR-BT alone is not sufficient enough.
      Neoadjuvant chemotherapy will be applied in high risk patients having muscle invasison, while
      intermediate risk patient - T1 high grade or carcinoma in situ patients - will be treated
      using Bacillus Calmette-Guerin (BCG) instilliations. After the completion of the neoadjuvant
      chemotherapy or BCG treatment, the patients will undergo the third MRI examination. Low risk
      patients will be followed by annual with MRI examination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of the multiparametric MRI (anatomical MRI, DCE-MRI, DWI) in the staging of bladder cancer</measure>
    <time_frame>24 months</time_frame>
    <description>The accuracy of multiparametric MRI (anatomical MRI, DCE-MRI, DWI) in the staging of bladder cancer will be evaluated using transurethral resection of bladder tumor and cystectomy specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of response to neo-adjuvant chemotherapy and/or BCG treatment evaluated by multiparametric MRI (anatomical MRI, DCE-MRI, DWI)</measure>
    <time_frame>24 months</time_frame>
    <description>The aim is to evaluate predictive power of multiparametric MRI for estimation neo-adjuvant chemotherapy and/or BCG treatment response. Multiparametric MRI will be performed before neo-adjuvant chemotherapy and/or BCG treatment and patients will be followed using standard clinical follow up and/or undergo cystectomy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Estimation of chemosensitivity</measure>
    <time_frame>24 months</time_frame>
    <description>Prevalence of patients responding neo-adjuvant chemotherapy, compared with the non-responders as evaluated by cystectomy specimens, according to various biomarkers and ex vivo tissue culturing will be evaluated.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>MRI and biomarkers in bladder cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Utilization of MR-imaging and biomarkers to stage bladder cancer and in estimation of chemosensitivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR imaging</intervention_name>
    <description>3 T MRI of the urinary bladder</description>
    <arm_group_label>MRI and biomarkers in bladder cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 to 85 years old

          -  Suspected BC based on cystoscopical evaluation.

          -  Mental status: Patients must be able to understand the meaning of the study

          -  Informed consent: The patient must sign the appropriate Ethical Committee (EC)
             approved informed consent documents in the presence of the designated staff

        Exclusion Criteria:

          -  History of serious cardiovascular, liver or kidney disease

          -  Uncontrolled serious infection

          -  Contraindications for MRI (cardiac pacemaker, intracranial clips etc)

          -  Patient refusing radical cystectomy or chemotherapy or BCG

          -  Intravesical Bacillus Calmette-Guerin instillations within 6 months before the first
             MRI examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Boström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, University of Turku and Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Boström, MD, PhD</last_name>
    <phone>+358 2 313 5925</phone>
    <email>peter.bostrom@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan Jambor, MD</last_name>
    <email>ivjamb@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Urology, Central Hospital of Pori</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antti Kaipia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Turku</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter J Bostrom, MD, PhD</last_name>
      <phone>+358-2-3135925</phone>
      <email>peter.bostrom@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Antti Salminen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Boström</investigator_full_name>
    <investigator_title>MD, PhD, Deah of Department</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>MRI</keyword>
  <keyword>TUR-BT</keyword>
  <keyword>cystectomy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

